Physician profile
Shail Dalal
NPI 1144241597
$188,882.06
in general payments reported to CMS, 2019-2025
54 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $31K · 2021: $38K · 2022: $43K · 2023: $29K · 2024: $20K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Honoraria: $12K · Food and Beverage: $8,160 · Travel and Lodging: $8,138 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,660 · Education: $1,036 · Long Term Medical Supply Or Device Loan: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,547.50 |
| Honoraria | $11,863.75 |
| Food and Beverage | $8,159.77 |
| Travel and Lodging | $8,137.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,660.00 |
| Education | $1,036.29 |
| Long Term Medical Supply Or Device Loan | $549.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $42,654.24 | 2020-2025 | Myrisk, Precisetumor, Mychoice Cdx |
| Astrazeneca Pharmaceuticals LP | $39,404.92 | 2020-2025 | Imfinzi, Lynparza, Calquence |
| Dova Pharmaceuticals | $27,234.69 | 2020-2021 | |
| Incyte Corporation | $10,942.12 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $9,845.69 | 2019-2024 | Lunsumio, Polivy, Tecentriq Hybreza |
| Pfizer INC. | $6,648.50 | 2020-2025 | |
| Daiichi Sankyo INC. | $6,117.29 | 2022-2025 | Datroway, Vanflyta |
| Merck Sharp & Dohme LLC | $4,169.20 | 2023-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Avyxa Pharma, LLC | $4,146.06 | 2025 | |
| Pharmacosmos Therapeutics INC. | $3,983.17 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,690.26 | 2023-2025 | |
| Gilead Sciences, INC. | $3,666.72 | 2021-2023 | |
| Exelixis INC. | $3,493.07 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $2,999.35 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Beigene USA, INC. | $2,536.57 | 2022-2024 | Brukinsa |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $2,075.00 | 2020-2021 | |
| Seagen INC. | $1,635.00 | 2022 | |
| Mirati Therapeutics, INC. | $1,487.50 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $1,271.77 | 2019-2025 | Iclusig |
| Astellas Pharma US INC | $1,235.33 | 2021-2025 | Padcev, Xospata, Vyloy |
| Blueprint Medicines Corporation | $1,198.92 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $828.49 | 2020-2024 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $823.91 | 2022-2025 | |
| Novocure INC. | $524.00 | 2019 | |
| Lilly USA, LLC | $509.14 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Beigene, LTD. | $450.00 | 2020 | |
| Abbvie INC. | $448.78 | 2024-2025 | |
| Sobi, INC | $435.18 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $400.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $379.69 | 2020-2025 | Opdivo |
| Cardinal Health 110 LLC | $375.00 | 2020-2025 | |
| Becton, Dickinson and Company | $366.67 | 2020 | |
| Amgen INC. | $348.25 | 2019-2023 | Vectibix, Xgeva, Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $304.72 | 2020-2023 | Imbruvica, Epkinly |
| Tempus Ai, INC | $257.71 | 2024-2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $251.08 | 2020-2025 | Libtayo |
| Novocure Gmbh | $200.00 | 2022 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $192.53 | 2019-2024 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $155.40 | 2023-2025 | |
| Array Biopharma INC | $124.33 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Eisai INC. | $123.42 | 2024-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Celgene Corporation | $94.48 | 2025 | Reblozyl, Breyanzi |
| Pharmaessentia USA Corporation | $86.99 | 2023-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $85.48 | 2023-2025 | Fotivda |
| Janssen Biotech, INC. | $78.20 | 2025 | Rybrevant, Tecvayli |
| Emd Serono, INC. | $66.49 | 2022-2024 | Bavencio |
| Geron Corporation | $55.85 | 2025 | Rytelo |
| Kite Pharma, INC. | $53.74 | 2023-2025 | Yescarta |
| Beone Medicines USA, INC. | $48.61 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $35.56 | 2021-2024 | Onivyde |
| Morphosys, US INC. | $24.47 | 2023 | Monjuvi |
| Tactile Systems Technology INC | $18.52 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shail Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.